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Abstract 
1p32 translocations and submicroscopic interstitial 
deletions resulting in TAL1 deregulation are known 
aberrations in T lymphoblastic leukemia/lymphoma. 
The t(1;5)(p32;q31) is a rare translocation of 1p32 
described only in 1 patient with aberrantly expressed 
TAL1 mRNA and protein (François et al., 1998) and 
in 2 other patients without involvement of the TAL1 
gene. 
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Clinics and pathology 
Disease 
Acute lymphocytic leukaemia (ALL) and acute 
promyelocytic leukemia (APL) 
Epidemiology 
Only 2 ALL cases reported: a 49-years old male with 
T-cell ALL (Cho et al., 2009) and a 10-years old 
male diagnosed with B-ALL (Kaleem et al., 2000). 
In addition, a t(1;5)(p32;q31) was detected as an 
additional anomaly in a 29-years old female patient 
diagnosed with acute promyelocyte leukemia 
(Zamecnikova, unpublished case). 
Prognosis 
Yet poorly known; the pediatric case with B-
precursor phenotype achieved complete remission 
after induction chemotherapy and remains in 
complete continuous remission for 24 months 
(Kaleem et al., 2000). Induction chemotherapy failed 
to induce remission in the adult patient with T-ALL 
and 5 months later the patient died due to renal 
failure and metabolic acidosis (Cho et al., 2009). In 
the APL case, induction was started with ATRA 
based therapy resulting in complete remission and 
she remains in complete remission for 14+ months. 
Cytogenetics 
t(1;5)(p32;q31) without TAL1 rearrangement  
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Figure 1.  Partial karyotypes with t(1;5)(p32;q31). 
Cytogenetics morphological 
May be overlooked in suboptimal preparations. 
 
Figure 2.  (A) Fluorescence in situ hybridization with LSI CSF1R (SpectrumOrange)/D5S23, D5S721 
(SpectrumGreen) showing the presence of 5q sequences on der(1) chromosome. (B) Hybridization with Vysis 
LSI 1p36 (SpectrumOrange) / LSI 1q25 (SpectrumGreen) probes showing translocation of 1p sequences to 
der(5) chromosome. 
Probes 
LSI CSF1R (SpectrumOrange/D5S23, D5S721 
SpectrumGreen, and Vysis LSI 1p36 
(SpectrumOrange) / LSI 1q25 (SpectrumGreen) 
probes. 
Additional anomalies 
Secondary anomaly in addition to t(8;14)(q11.2;q32) 
in a pediatic B-ALL patient (Kaleem et al., 2000), 
associated with del(6q) in a sideline in the T-ALL 
case (Cho et al., 2009) and found in association 
witht(15;17)(q24;q21) in the APL case. 
Result of the chromosomal 
anomaly 
Fusion protein 
Oncogenesis 
Because of its rarity, the role of t(1;5)(p32;q31) in 
disease pathogenesis as well as its clinical 
significance is unclear. Unlike in the T-ALL case 
described by François et al., 1998, neither TAL1 
translocation nor its aberrant expression was 
detected FISH and by immunohistochemical 
staining in the other T-ALL patient (Cho et al., 
2009). Therefore it is likely that some other genes  
 
located at 1p32 such as BLYM, EPS15, CDKN2C, 
and JUN may be involved in leukemogenesis (Cho 
et al., 2009). In the remaining 2 cases, 
t(1;5)(p32;q31) was found in addition to 
t(8;14)(q11.2;q32) and to t(15;17)(q24;q21)  likely 
representing a secondary event in these cases. 
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